Back to Search
Start Over
Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data.
- Source :
-
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension [High Blood Press Cardiovasc Prev] 2024 Mar; Vol. 31 (2), pp. 215-219. Date of Electronic Publication: 2024 Feb 03. - Publication Year :
- 2024
-
Abstract
- Introduction: Familial hypercholesterolemia is a common genetic condition that significantly increases an individual's risk of cardiovascular events such as heart attack, stroke, and cardiac death and is a candidate for population-wide screening programs. Economic analyses of strategies to identify and treat familial hypercholesterolemia are limited by a lack of real-world cost estimates for screening services and medications for reducing cardiovascular risk in this population.<br />Methods: We estimated the cost of lipid panel testing in patients with hyperlipidemia and the cost of statins, ezetimibe, and PCKS9 inhibitors in patients with familial hypercholesterolemia from a commercial claims database and report costs and charges per panel and prescription by days' supply.<br />Results: The mean cost for a 90-day supply for statins was $183.33, 2.3 times the mean cost for a 30-day supply at $79.35. PCSK9 inhibitors generated the highest mean costs among medications used by patients with familial hypercholesterolemia.<br />Conclusions: Lipid testing and lipid-lowering medications for cardiovascular disease prevention generate substantial real-world costs which can be used to improve cost-effectiveness models of familial hypercholesterolemia screening and care management.<br /> (© 2024. Italian Society of Hypertension.)
- Subjects :
- Humans
Male
Treatment Outcome
Middle Aged
Female
Cost-Benefit Analysis
Time Factors
Models, Economic
Ezetimibe therapeutic use
Ezetimibe economics
Serine Proteinase Inhibitors therapeutic use
Serine Proteinase Inhibitors economics
Adult
Heart Disease Risk Factors
Lipids blood
Hyperlipoproteinemia Type II economics
Hyperlipoproteinemia Type II drug therapy
Hyperlipoproteinemia Type II diagnosis
Hyperlipoproteinemia Type II epidemiology
Hyperlipoproteinemia Type II blood
Drug Costs
Administrative Claims, Healthcare
Cardiovascular Diseases prevention & control
Cardiovascular Diseases economics
Cardiovascular Diseases epidemiology
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors economics
PCSK9 Inhibitors
Databases, Factual
Anticholesteremic Agents therapeutic use
Anticholesteremic Agents economics
Biomarkers blood
Proprotein Convertase 9
Subjects
Details
- Language :
- English
- ISSN :
- 1179-1985
- Volume :
- 31
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
- Publication Type :
- Academic Journal
- Accession number :
- 38308804
- Full Text :
- https://doi.org/10.1007/s40292-024-00624-6